secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001193125-22-283667
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology reports Q3 net loss $24.9M; initiates pivotal zipalertinib study
--------------------------------------------------------------------------------

- Initiated pivotal study for zipalertinib in EGFR exon 20 NSCLC; cohort to evaluate 150 mg BID with food.
- Increased ownership in MICA (CLN-619) from 54% to 92% for $30.7M cash.
- Cash and investments $606.7M at Sept 30, 2022; runway extends beyond key milestones.
- Net loss before noncontrolling interest $24.9M; R&D expenses $19.7M, G&A $10.1M.
- Appointed Jacquelyn Sumer as CLO and Dr. David Ryan to Board; IND filings for CLN-617, CLN-978 on track for H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522283667/0001193125-22-283667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522283667/d371812d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-283667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer